First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.

导出原文传递

翻译打印收藏纠错

第一作者： Neeta,Somaiah

第一单位： Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas. nsomaiah@mdanderson.org.

作者： Neeta,Somaiah ^[1] ; Matthew S,Block ^[2] ; Joseph W,Kim ^[3] ; Geoffrey I,Shapiro ^[4] ; Khanh T,Do ^[4] ; Patrick,Hwu ^[5] ; Joseph P,Eder ^[3] ; Robin L,Jones ^[6] ; Hailing,Lu ^[7] ; Jan H,Ter Meulen ^[8] ; Chet,Bohac ^[8] ; Michael,Chen ^[8] ; Frank J,Hsu ^[8] ; Sacha,Gnjatic ^[8] ; Seth M,Pollack ^[9]

作者单位： Department of Sarcoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas. nsomaiah@mdanderson.org. ^[1] Department of Oncology, Mayo Clinic, Rochester, Minnesota. ^[2] Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut. ^[3] Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[4] Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, Texas. ^[5] Division of Oncology, University of Washington, Seattle, Washington. ^[6] Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[7] Immune Design Corp., Seattle, Washington and South San Francisco, California. ^[8] Immune Monitoring Center, Icahn School of Medicine at Mount Sinai, New York, New York. ^[9]